Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL
- PMID: 25362178
- PMCID: PMC4239212
- DOI: 10.4049/jimmunol.1401161
Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL
Abstract
We previously demonstrated that HIV replication is concentrated in lymph node B cell follicles during chronic infection and that HIV-specific CTL fail to accumulate in large numbers at those sites. It is unknown whether these observations can be generalized to other secondary lymphoid tissues or whether virus compartmentalization occurs in the absence of CTL. We evaluated these questions in SIVmac239-infected rhesus macaques by quantifying SIV RNA(+) cells and SIV-specific CTL in situ in spleen, lymph nodes, and intestinal tissues obtained at several stages of infection. During chronic asymptomatic infection prior to simian AIDS, SIV-producing cells were more concentrated in follicular (F) compared with extrafollicular (EF) regions of secondary lymphoid tissues. At day 14 of infection, when CTL have minimal impact on virus replication, there was no compartmentalization of SIV-producing cells. Virus compartmentalization was diminished in animals with simian AIDS, which often have low-frequency CTL responses. SIV-specific CTL were consistently more concentrated within EF regions of lymph node and spleen in chronically infected animals regardless of epitope specificity. Frequencies of SIV-specific CTL within F and EF compartments predicted SIV RNA(+) cells within these compartments in a mixed model. Few SIV-specific CTL expressed the F homing molecule CXCR5 in the absence of the EF retention molecule CCR7, possibly accounting for the paucity of F CTL. These findings bolster the hypothesis that B cell follicles are immune privileged sites and suggest that strategies to augment CTL in B cell follicles could lead to improved viral control and possibly a functional cure for HIV infection.
Copyright © 2014 by The American Association of Immunologists, Inc.
Figures








Similar articles
-
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.PLoS Pathog. 2022 Feb 7;18(2):e1009831. doi: 10.1371/journal.ppat.1009831. eCollection 2022 Feb. PLoS Pathog. 2022. PMID: 35130312 Free PMC article.
-
Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.Front Immunol. 2018 Mar 20;9:492. doi: 10.3389/fimmu.2018.00492. eCollection 2018. Front Immunol. 2018. PMID: 29616024 Free PMC article.
-
Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.J Virol. 2000 Aug;74(16):7485-95. doi: 10.1128/jvi.74.16.7485-7495.2000. J Virol. 2000. PMID: 10906202 Free PMC article.
-
Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.Immunol Rev. 1999 Aug;170:127-34. doi: 10.1111/j.1600-065x.1999.tb01334.x. Immunol Rev. 1999. PMID: 10566147 Review.
-
Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection.Immunol Rev. 2001 Oct;183:115-26. doi: 10.1034/j.1600-065x.2001.1830110.x. Immunol Rev. 2001. PMID: 11782252 Review.
Cited by
-
Challenges and strategies for the eradication of the HIV reservoir.Curr Opin Immunol. 2016 Oct;42:65-70. doi: 10.1016/j.coi.2016.05.015. Epub 2016 Jun 9. Curr Opin Immunol. 2016. PMID: 27288651 Free PMC article. Review.
-
Compartmental structure in the secondary lymphoid tissue can slow down in vivo HIV-1 evolution in the presence of strong CTL responses.J R Soc Interface. 2025 Feb;22(223):20240468. doi: 10.1098/rsif.2024.0468. Epub 2025 Feb 26. J R Soc Interface. 2025. PMID: 39999881
-
The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence.J Immunol. 2016 Jul 15;197(2):407-17. doi: 10.4049/jimmunol.1600343. J Immunol. 2016. PMID: 27382129 Free PMC article. Review.
-
Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations.Mol Ther Methods Clin Dev. 2019 Sep 30;16:1-10. doi: 10.1016/j.omtm.2019.09.007. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2019. PMID: 31673565 Free PMC article.
-
Follicular T-cell subsets in HIV infection: recent advances in pathogenesis research.Curr Opin HIV AIDS. 2019 Mar;14(2):71-76. doi: 10.1097/COH.0000000000000525. Curr Opin HIV AIDS. 2019. PMID: 30585797 Free PMC article. Review.
References
-
- Connick E, Mattila T, Folkvord JM, Schlichtemeier R, Meditz AL, Ray MG, McCarter MD, Mawhinney S, Hage A, White C, Skinner PJ. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol. 2007;178:6975–6983. - PubMed
-
- Folkvord JM, Armon C, Connick E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res Hum Retroviruses. 2005;21:363–370. - PubMed
-
- Hufert FT, van Lunzen J, Janossy G, Bertram S, Schmitz J, Haller O, Racz P, von Laer D. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. Aids. 1997;11:849–857. - PubMed
-
- Tenner-Racz K, Stellbrink HJ, van Lunzen J, Schneider C, Jacobs JP, Raschdorff B, Grosschupff G, Steinman RM, Racz P. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J Exp Med. 1998;187:949–959. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI090795/AI/NIAID NIH HHS/United States
- P51 RR000167/RR/NCRR NIH HHS/United States
- R01 AI096966/AI/NIAID NIH HHS/United States
- T32 AI007447/AI/NIAID NIH HHS/United States
- R56AI080418/AI/NIAID NIH HHS/United States
- R01AI090795/AI/NIAID NIH HHS/United States
- HHSN272201300006C/AI/NIAID NIH HHS/United States
- U24 AI126683/AI/NIAID NIH HHS/United States
- P51RR000167/RR/NCRR NIH HHS/United States
- R56 AI080418/AI/NIAID NIH HHS/United States
- HHSN272200900037C/AI/NIAID NIH HHS/United States
- R24 RR016001/RR/NCRR NIH HHS/United States
- P51 OD011106/OD/NIH HHS/United States
- P51OD011106/OD/NIH HHS/United States
- R01AI096966/AI/NIAID NIH HHS/United States
- HHSN 2722000900037C/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources